Patent classifications
C07D307/85
FORMULATIONS OF HISTONE DEACETYLASE INHIBITOR AND USES THEREOF
Dosing regimens, methods of treatment, controlled release formulations, and combination therapies that include an HDAC inhibitor, or a pharmaceutically acceptable salt thereof, are described.
BCKDK INHIBITORS AND/OR DEGRADERS
Described herein are compounds of Formula I,
##STR00001##
wherein the variables are defined herein, their use as branched-chain alpha keto acid dehydrogenase kinase inhibitors and/or degraders, pharmaceutical compositions containing such compounds and their use to treat, for example, diabetes, kidney disease, NASH and heart failure.
NEW SALT OF ABEXINOSTAT, ASSOCIATED CRYSTALLINE FORM, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
Abexinostat tosylate of formula (II):
##STR00001##
and its crystalline form I characterised by its X-ray powder diffraction diagram, its Raman spectrum and its solid-state .sup.13C CP/MAS NMR spectrum.
Medicinal products containing the same which are useful in the treatment of cancer.
NEW SALT OF ABEXINOSTAT, ASSOCIATED CRYSTALLINE FORM, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
Abexinostat tosylate of formula (II):
##STR00001##
and its crystalline form I characterised by its X-ray powder diffraction diagram, its Raman spectrum and its solid-state .sup.13C CP/MAS NMR spectrum.
Medicinal products containing the same which are useful in the treatment of cancer.
Compositions including 6-aminohexanoic acid derivatives as HDAC inhibitors
This invention relates to compounds of Formula (I) wherein Cy.sup.1, L.sup.1, Y, R.sup.1, L.sup.2, and Ar2 are defined herein, for the treatment of cancers, inflammatory disorders, and neurological conditions. ##STR00001##
Compositions including 6-aminohexanoic acid derivatives as HDAC inhibitors
This invention relates to compounds of Formula (I) wherein Cy.sup.1, L.sup.1, Y, R.sup.1, L.sup.2, and Ar2 are defined herein, for the treatment of cancers, inflammatory disorders, and neurological conditions. ##STR00001##
BENZOFURAN ANALOGUE AS NS4B INHIBITOR
Provided is a benzofuran analogue having a structure represented by formula (I) and used as an NS4B inhibitor, or a pharmaceutically acceptable salt of the benzofuran analogue. The benzofuran analogue has anti-hepatitis C virus activity.
BENZOFURAN ANALOGUE AS NS4B INHIBITOR
Provided is a benzofuran analogue having a structure represented by formula (I) and used as an NS4B inhibitor, or a pharmaceutically acceptable salt of the benzofuran analogue. The benzofuran analogue has anti-hepatitis C virus activity.
AMINO ACID TRANSPORT INHIBITORS AND THE USES THEREOF
These compounds are glutamine transporter inhibitors, e.g., alanine, serine, cysteine-preferring transporter 2 (ASCT2) inhibitors. Glutamine transporter inhibitors are useful to treat a variety of diseases, disorders, or conditions including cancer.
AMINO ACID TRANSPORT INHIBITORS AND THE USES THEREOF
These compounds are glutamine transporter inhibitors, e.g., alanine, serine, cysteine-preferring transporter 2 (ASCT2) inhibitors. Glutamine transporter inhibitors are useful to treat a variety of diseases, disorders, or conditions including cancer.